The time has not yet come to remove your chips from the table: Recursion Pharmaceuticals Inc. (RXRX)

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) stock jumped 11.01% on Friday to $9.78 against a previous-day closing price of $8.81. With 1.39 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.01 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.93 whereas the lowest price it dropped to was $9.10. The 52-week range on RXRX shows that it touched its highest point at $31.84 and its lowest point at $4.92 during that stretch. It currently has a 1-year price target of $16.00.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RXRX was up-trending over the past week, with a rise of 20.00%, but this was up by 10.51% over a month. Three-month performance surged to 50.69% while six-month performance fell -20.87%. The stock lost -68.80% in the past year, while it has lost -42.91% so far this year. A look at the trailing 12-month EPS for RXRX yields -1.30 with Next year EPS estimates of -1.68. For the next quarter, that number is -0.37. This implies an EPS growth rate of -177.30% for this year and -0.70% for next year.

Float and Shares Shorts:

At present, 170.69 million RXRX shares are outstanding with a float of 150.98 million shares on hand for trading. On Jul 14, 2022, short shares totaled 15.99 million, which was 9.30% higher than short shares on Jun 14, 2022. In addition to Dr. Christopher C. Gibson Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Tina Marriott Larson serves as its COO & Pres.

Institutional Ownership:

Through their ownership of 77.26% of RXRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 30.01% of RXRX, in contrast to 26.05% held by mutual funds. Shares owned by individuals account for 16.04%. As the largest shareholder in RXRX with 13.42% of the stake, Baillie Gifford & Co. holds 21,981,604 shares worth 21,981,604. A second-largest stockholder of RXRX, The Vanguard Group, Inc., holds 6,424,848 shares, controlling over 3.92% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in RXRX, holding 5,896,609 shares or 3.60% stake. With a 8.53% stake in RXRX, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 13,967,496 shares are owned by the mutual fund manager. The Vanguard US Growth Fund, which owns about 1.93% of RXRX stock, is the second-largest Mutual Fund holder. It holds 3,162,093 shares valued at 25.74 million. iShares Russell 2000 ETF holds 1.81% of the stake in RXRX, owning 2,967,837 shares worth 24.16 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RXRX since 5 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RXRX analysts setting a high price target of $38.00 and a low target of $7.00, the average target price over the next 12 months is $16.00. Based on these targets, RXRX could surge 288.55% to reach the target high and fall by -28.43% to reach the target low. Reaching the average price target will result in a growth of 63.6% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RXRX will report FY 2022 earnings on 03/22/2023. Analysts have provided yearly estimates in a range of -$1.19 being high and -$1.96 being low. For RXRX, this leads to a yearly average estimate of -$1.57. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Recursion Pharmaceuticals Inc. surprised analysts by -$0.43 when it reported -$0.33 EPS against a consensus estimate of $0.10. The surprise factor in the prior quarter was -$0.07. Based on analyst estimates, the high estimate for the next quarter is -$0.33 and the low estimate is -$0.43. The average estimate for the next quarter is thus -$0.37.

Summary of Insider Activity:

Insiders traded RXRX stock several times over the past three months with 21 Buys and 14 Sells. In these transactions, 192,250 shares were bought while 65,323 shares were sold. The number of buy transactions has increased to 84 while that of sell transactions has risen to 66 over the past year. The total number of shares bought during that period was 1,740,543 while 5,237,361 shares were sold.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]